A significant proportion of heavily pretreated @entity1 with metastatic @entity14 maintain good performance status (PS) and are eligible for further systemic treatment. @entity1138  ( @entity1139 ) combined with @entity416 can be considered as salvage treatment in this group of @entity1 . To evaluate the efficacy and @entity137 of @entity1138  and @entity416 as at least third-line systemic therapy (after failure of @entity1487 , @entity2600 , @entity901 -based chemotherapy regimens and targeted therapies) in @entity1 with metastatic @entity14 . A  total of 31 @entity1 with a  median age of 55.2 years with metastatic @entity14 received salvage chemotherapy at the Oncological Department of University Hospital in Krakow, Poland, between July 2011 and July 2014. Chemotherapy consisted of intravenous @entity1139 6 mg/m2 on day 1 and oral @entity416 1000 mg/m2 twice daily on days 1-14 followed by a  7-day treatment-free interval. Each cycle was repeated every 3 weeks unless there was evidence of disease progression or unacceptable @entity137 . All the31 @entity1 were evaluable for response and @entity137 . A  total of 113 cycles were administered. Five of the 31 (16.1%) @entity1 had stable disease after three cycles of chemotherapy, 24 (77.4%) @entity1 progressed and 1 (3.2%) @entity1 is still undergoing treatment. One @entity1 (3.2%) died due to @entity1188 5 days after starting treatment. Median progression free survival (PFS) was 2.5 months. Median overall survival (OS) was 4.9 months. @entity137 was mild and easily manageable. @entity1138  and @entity416 can be considered as salvage therapy in heavily pretreated @entity1 with metastatic @entity14 and with good performance status. @entity137 of these drugs combination is moderate and easily manageable.

Salvage chemotherapy in metastatic @entity14 with the combination of @entity416 and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C', 'Mitomycin C'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['cardiac infarct'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5Fu']
@entity1138 :: (MESH:D016685,Chemical) :: ['mitomycin C']
